Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$44.24 USD
+0.39 (0.89%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $44.23 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RARE 44.24 +0.39(0.89%)
Will RARE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RARE
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key Metrics
Other News for RARE
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
Ultragenyx price target raised by $2 at TD Cowen, here's why
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)
First Week of RARE June 21st Options Trading
Wall Street Analysts Are Bullish on Top Healthcare Picks